Bone Biologics (BBLG) Change in Accured Expenses (2010 - 2025)
Bone Biologics (BBLG) posted quarterly Change in Accured Expenses of $84803.0 for Q4 2025, down 53.66% year-over-year from $182985.0 in Q4 2024, and up 220.04% quarter-over-quarter from -$70648.0 in Q3 2025.
Powered by 
Analysis
Bone Biologics (BBLG) Change in Accured Expenses (2010 - 2025) Analysis & Trends
Bone Biologics (BBLG) has reported Change in Accured Expenses for 16 consecutive years, with $84803.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Change in Accured Expenses fell 53.66% year-over-year to $84803.0; the TTM figure through Dec 2025 stood at $91025.0 (up 1.39% YoY), while the FY2025 annual figure was $91025.0, up 1.39% from the prior year.
- Change in Accured Expenses climbed to $84803.0 in Q4 2025 per BBLG's latest filing, from -$70648.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $728839.0 in Q3 2022 and bottomed at -$694689.0 in Q4 2022.
- Historically, Change in Accured Expenses has averaged $3803.6 across 5 years, with a median of $22678.5 in 2021.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses tumbled 2444.23% — and 2023, when it surged 4131.15%.
- Bone Biologics' Change in Accured Expenses stood at $29634.0 in 2021, then sank by 2444.23% to -$694689.0 in 2022, then jumped by 130.66% to $213017.0 in 2023, then declined by 14.1% to $182985.0 in 2024, then tumbled by 53.66% to $84803.0 in 2025.
- Business Quant data shows BBLG's Change in Accured Expenses at $84803.0 in Q4 2025, -$70648.0 in Q3 2025, and $155886.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - | 55.78 Mn |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn | 212.44 Mn |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Bone Biologics | 1.00 Mn | 1.00 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 84,803.00 |
| Sep 30, 2025 | -70,648.00 |
| Jun 30, 2025 | 155,886.00 |
| Mar 31, 2025 | -79,016.00 |
| Dec 31, 2024 | 182,985.00 |
| Sep 30, 2024 | -41,815.00 |
| Jun 30, 2024 | 85,686.00 |
| Mar 31, 2024 | -137,076.00 |
| Dec 31, 2023 | 213,017.00 |
| Sep 30, 2023 | -664,022.00 |
| Jun 30, 2023 | 665,263.00 |
| Mar 31, 2023 | 41,618.00 |
| Dec 31, 2022 | -694,689.00 |
| Sep 30, 2022 | 728,839.00 |
| Jun 30, 2022 | 15,723.00 |
| Mar 31, 2022 | -44,996.00 |
| Dec 31, 2021 | 29,634.00 |
| Sep 30, 2021 | -13,962.00 |
| Jun 30, 2021 | -419,100.00 |
| Mar 31, 2021 | 37,941.00 |